Resistance and support
117.73
![](https://www.icicidirect.com/Content/images/graph17.png)
Financials( ₹ in Cr) | Bal Pharma Ltd | Sun Pharmaceuticals Industries Ltd | Divis Laboratories Ltd | Cipla Ltd | Zydus Lifesciences Ltd |
---|---|---|---|---|---|
Price | 117.69 | 1,520.85 | 4,596.45 | 1,480.80 | 1,073.95 |
% Change | 0.94 | 0.30 | 1.64 | -0.01 | 1.60 |
Mcap ₹ Cr | 186.00 | 364,902.86 | 122,021.50 | 119,554.91 | 108,064.50 |
Revenue TTM ₹ Cr | 304.22 | 43,885.68 | 7,767.51 | 15,790.60 | 17,237.40 |
Net Profit TTM ₹ Cr | 2.62 | 8,560.84 | 1,823.38 | 2,513.47 | 1,997.30 |
PE TTM | 25.11 | 36.50 | 76.24 | 28.08 | 28.04 |
1 Year Return | 29.40 | 48.84 | 27.62 | 46.72 | 84.38 |
ROCE | 9.16 | 16.79 | 19.30 | 14.76 | 16.25 |
ROE | 4.28 | 16.46 | 14.89 | 10.66 | 14.05 |
Equity Capital: 63.79 Cr FV: 10.00
Period | MF Net Purchase / (sold) | FII Net |
---|---|---|
LAST 1M | 29,542.69 | 26,564.54 |
LAST 3M | 107,300.08 | -872.81 |
LAST 6M | 187,950.75 | 839.71 |
LAST 12M | 304,454.24 | 86,051.23 |
Date | Action Type | Ratio |
---|---|---|
Sep 18, 2023 | Dividend | 10 |
Sep 13, 2022 | Dividend | 10 |
Bal Pharma Ltd (BPL), a member of the Mcro Laboratories Group, was incorporated as a private limited company in May `87. In Mar.`90, BPL took over a pharmaceutical products manufacturing unit located in Bangalore through the Karnataka State Finance Corporation for a consideration of Rs 25.18 lac following which, BPL commenced manufacturing formulations. BPL manufactures and markets pharmaceutical formulations -- paracetamol, aluminium hydroxide, povidone iodine, alprazolam, gliclazide, griseofulvin, lactobacillus, rifampicin, piroxicam amoxycillin, etc. The company promotes its products through the common sales force of the group but proposes to induct its own soon. It came out with a public issue in Feb.`95 for manufacture of bulk drugs and expansion of pharmaceutical formulations. During 1997-98, the formalities of takeover of the unit from Lakme Limited have been completed and effective from 23rd July, 1997 the unit has become a division of Bal Pharma Limited. The company`s product range has been expanded with the introduction of AZIWIN, CAFIMOL & CORTIDERM. The company has added further product range Zanovid, Aziwin, Dry Syrup, Meloxi, Ocium - M, Progit - MPS in its ethical division during 1999-2000. As part of the expansion of the product range, the company has introduced Cardiac Specialities Products. To market these products, a new division named "SERVETUS" has started functioning during 2001. New products like Amiloride,Benzydamine and Ebastine were rolled into the market during 2002. The commercial production of Formulation Plant in Uttarakhand started from 1st January, 2009. The Company floated Lifezen Healthcare Pvt Ltd during the year 2014-15 as its subsidiary. It ventured into heath care sector through its subsidiary i.e. Balance Clinics LLP. In 2016-17, it commenced its project on construction of an fully integrated API unit with an annual production capacity of 270 metric tonnes of assorted API products including Gliclazide, Ebastine, Amiloride HCL, Benzydamine HCL, Pregablin etc, located at Gauribidanur near Bangalore with an estimated investment of Rs 45 Crores. In 2017-18, the Company acquired 100% stake and management control of Golden Drugs Private Ltd, an Udaipur, Rajasthan involved in the manufacture of bulk drugs and intermediates costing Rs 14 Crores. It earmarked Rs. 36 Cr. for setting up of an bulk drug`s manufacturing unit at Yadgir District , Karnataka in year 2022-23. It launched Sitagliptin (a DPP-4 Inhibitor) in the plain form, and as a combination with Metformin under the brand names SITABEND & SITABEND-M, respectively in 2023.
21 & 22 Bommasandra Indl Area, Hosur Road, Bangalore, Karnataka, 560092
: | investor:balpharma.com | |
Website | : | http://www.balpharma.com |
TSR Consultants P Ltd
AGM Date (Month) | : | Sep |
Face Value Equity Shares | : | 10 |
Market Lot Equity Shares | : | 1 |
BSE Code | : | 524824 |
NSE Code | : | BALPHARMA |
Book Closure Date (Month) | : | Sep |
BSE Group | : | B |
ISIN | : | INE083D01012 |
You can buy Bal Pharma Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Bal Pharma Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of Jun 28, 2024 03:44 PM the closing price of Bal Pharma Ltd was Rs.117.69.
The latest PE ratio of Bal Pharma Ltd as of Jun 28, 2024 03:44 PM is 25.11
The latest PB ratio of Bal Pharma Ltd as of Jun 28, 2024 03:44 PM is 0.37
The 52-week high of Bal Pharma Ltd share price is Rs. 132.45 while the 52-week low is Rs. 81.20
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Jun 28, 2024 03:44 PM, the market cap of Bal Pharma Ltd stood at Rs. 186.00 Cr.